GAIA 102
Alternative Names: GAIA-102Latest Information Update: 10 Nov 2022
At a glance
- Originator GAIA BioMedicine
- Developer GAIA BioMedicine; Kyushu University
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Gastric cancer; Non-small cell lung cancer; Pancreatic cancer
- Phase I Neuroblastoma; Solid tumours
Most Recent Events
- 26 Oct 2022 Phase-I clinical trials in Neuroblastoma (Second-line therapy or greater, Combination therapy, In adolescents, In adults, In children, In infants) in Japan (IV) (NCT05608148)
- 26 Oct 2022 Phase-I clinical trials in Neuroblastoma (Second-line therapy or greater, Monotherapy, In infants, In children, In adolescents, In adults) in Japan (IV) (NCT05608148)
- 26 Oct 2022 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, In children, In adults, In infants, In adolescents, Metastatic disease, Combination therapy) in Japan (IV) (NCT05608148)